Vantage Consulting Group’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q3
Sell
-268
Closed -$243K 100
2024
Q2
$243K Sell
268
-44
-14% -$35.2K 0.18% 106
2024
Q1
$243K Sell
312
-78
-20% -$55.5K 0.15% 134
2023
Q4
$227K Sell
390
-6
-2% -$3.5K 0.15% 168
2023
Q3
$213K Sell
396
-119
-23% -$61.3K 0.14% 168
2023
Q2
$242K Sell
515
-247
-32% -$104K 0.14% 145
2023
Q1
$262K Buy
762
+91
+14% +$30.7K 0.15% 130
2022
Q4
$245K Sell
671
-141
-17% -$50K 0.14% 138
2022
Q3
$263K Buy
812
+6
+0.7% +$1.9K 0.15% 98
2022
Q2
$261K Sell
806
-57
-7% -$17.1K 0.15% 105
2022
Q1
$247K Sell
863
-201
-19% -$51.7K 0.1% 148
2021
Q4
$294K Buy
1,064
+50
+5% +$12.7K 0.08% 98
2021
Q3
$234K Buy
1,014
+6
+0.6% +$1.48K 0.05% 156
2021
Q2
$231K Buy
+1,008
New +$202K 0.04% 162
2021
Q1
Sell
-458
Closed -$77K 904
2020
Q4
$77K Buy
+458
New +$68.4K 0.01% 267

Other funds holding LLY

Vantage Consulting Group's LLY Position: Q3 2024 in Review

Vantage Consulting Group sold out of Eli Lilly (LLY) in Q3 2024, closing a stake of 268 shares — an estimated $243K sold.

Vantage Consulting Group first reported a position in LLY in Q4 2020 and held it in 14 quarters. The position peaked at $294K in Q4 2021. 3,657 funds tracked by Wall St. Rank hold LLY as of Q3 2024.

  • Vantage Consulting Group reported no remaining Eli Lilly position as of Q3 2024 after selling out during the quarter.
  • Vantage Consulting Group sold 268 Eli Lilly shares in Q3 2024, an estimated $243K.
  • Vantage Consulting Group first reported a position in Eli Lilly in Q4 2020 and held it in 14 quarters.
  • Vantage Consulting Group's Eli Lilly position peaked at $294K in Q4 2021.
  • 3,657 funds tracked by Wall St. Rank held Eli Lilly as of Q3 2024.

Based on Vantage Consulting Group's 13F filing for Q3 2024, filed 14 Nov 2024.